These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18410043)

  • 21. Resolution of epoetin-induced pure red cell aplasia 2 years later, successful re-challenge with continuous erythropoiesis receptor stimulator.
    Lim SK; Bee PC; Keng TC; Chong YB
    Clin Nephrol; 2013 Sep; 80(3):227-30. PubMed ID: 23298519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin.
    Ryan MH; Heavner GA; Brigham-Burke M; McMahon F; Shanahan MF; Gunturi SR; Sharma B; Farrell FX
    Int Immunopharmacol; 2006 Apr; 6(4):647-55. PubMed ID: 16504928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.
    Stravitz RT; Chung H; Sterling RK; Luketic VA; Sanyal AJ; Price AS; Purrington A; Shiffman ML
    Am J Gastroenterol; 2005 Jun; 100(6):1415-9. PubMed ID: 15929778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks.
    Naughton CA; Duppong LM; Forbes KD; Sehgal I
    Am J Health Syst Pharm; 2003 Mar; 60(5):464-8. PubMed ID: 12635452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.
    Lim LC
    Hematology; 2005 Jun; 10(3):255-9. PubMed ID: 16019474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis.
    Asari A; Gokal R
    J Am Soc Nephrol; 2004 Aug; 15(8):2204-7. PubMed ID: 15284306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02.
    Tan CW; Tan-Koi WC; Ng J; Chan CM; Hwang WY
    Pharmacogenomics; 2016 Jul; 17(11):1235-1243. PubMed ID: 27348021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of illegal trade on the quality of epoetin alfa in Thailand.
    Fotiou F; Aravind S; Wang PP; Nerapusee O
    Clin Ther; 2009 Feb; 31(2):336-46. PubMed ID: 19302906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of biologic follow-ons: experience with EPO.
    Casadevall N; Rossert J
    Best Pract Res Clin Haematol; 2005; 18(3):381-7. PubMed ID: 15792912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eprex (recombinant human erythropoietin alfa) and pure red cell aplasia--recommendations for administration to patients with CRF.
    S Afr Med J; 2003 Nov; 93(11):839. PubMed ID: 14677505
    [No Abstract]   [Full Text] [Related]  

  • 31. Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.
    Hermeling S; Jiskoot W; Crommelin DJ; Schellekens H
    Pharm Res; 2006 Mar; 23(3):641-2; author reply 643-4. PubMed ID: 16525860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?
    Hermeling S; Schellekens H; Crommelin DJ; Jiskoot W
    Pharm Res; 2003 Dec; 20(12):1903-7. PubMed ID: 14725351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pure red cell aplasia developed during treatment with erythropoietin. Complete remission during immunosuppressive therapy].
    Høi-Hansen T; Lauritzen AM; Hansen PB
    Ugeskr Laeger; 2003 May; 165(19):2001-2. PubMed ID: 12795077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
    Macdougall IC; Roche A; Rossert J; Casadevall N; Francois P; Kemeny DM
    Nephrol Dial Transplant; 2004 Nov; 19(11):2901-5. PubMed ID: 15496566
    [No Abstract]   [Full Text] [Related]  

  • 35. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity.
    Seidl A; Hainzl O; Richter M; Fischer R; Böhm S; Deutel B; Hartinger M; Windisch J; Casadevall N; London GM; Macdougall I
    Pharm Res; 2012 Jun; 29(6):1454-67. PubMed ID: 22094831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.
    Macdougall IC; Roger SD; de Francisco A; Goldsmith DJ; Schellekens H; Ebbers H; Jelkmann W; London G; Casadevall N; Hörl WH; Kemeny DM; Pollock C
    Kidney Int; 2012 Apr; 81(8):727-32. PubMed ID: 22336988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pure red cell aplasia in erythropoietin therapy in patients with kidney failure].
    Opatrný K
    Cas Lek Cesk; 2003; 142(12):741-5. PubMed ID: 14746223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin-induced, antibody-mediated pure red cell aplasia.
    Rossert J;
    Eur J Clin Invest; 2005 Dec; 35 Suppl 3():95-9. PubMed ID: 16281965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing anaemia management with subcutaneous administration of epoetin.
    Besarab A
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi10-5. PubMed ID: 15958820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of an Oxidizing Leachable from a Clinical Syringe Rubber Stopper.
    Schröter A; Peter S; Mahler HC; Zerr A; Danton O; Chalus P; Koulov AV; Huwyler J; Jahn M
    J Pharm Sci; 2021 Oct; 110(10):3410-3417. PubMed ID: 34089713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.